<?xml version="1.0" encoding="UTF-8"?>
<results title="funders">
 <result pre="epidemics. CEPI is focusing on supporting candidate vaccines against the" exact="World Health Organization" post="(WHO) Blueprint priority pathogens MERS-CoV, Nipah virus, Lassa fever"/>
 <result pre="lost and economic burden. A report prepared by the U.S." exact="National Academy of Sciences" post="in 2016 estimated that over 10 years the global"/>
 <result pre="Norway and India, the Bill &amp;amp; Melinda Gates Foundation, the" exact="Wellcome Trust," post="and the World Economic Forum. From 2017 CEPI has"/>
 <result pre="including multiyear funding from Norway, Germany, Japan, Canada, Australia, the" exact="European Commission," post="the Bill &amp;amp; Melinda Gates Foundation, and the Wellcome"/>
 <result pre="European Commission, the Bill &amp;amp; Melinda Gates Foundation, and the" exact="Wellcome Trust." post="It has also received single-year investments from the governments"/>
 <result pre="Japan US$125 million 125 Multiyear Germany €90 million 102.4 Multiyear" exact="Wellcome Trust" post="US$100.4 million 100.4 Multiyear Bill &amp;amp; Melinda Gates Foundation"/>
 <result pre="Multiyear Bill &amp;amp; Melinda Gates Foundation US$100 million 100 Multiyear" exact="European Commission" post="€80 million 89.6 Multiyear United Kingdom £10 million 12.6"/>
 <result pre="to the delivery and stockpiling of new vaccines. ( NIH" exact="National Institutes of Health;" post="IMI Innovative Medicines Initiative; GloPID‑R Global Research Collaboration for"/>
 <result pre="Initiative; GloPID‑R Global Research Collaboration for Infectious Disease Preparedness; EC" exact="European Commission;" post="BMGF Bill &amp;amp; Melinda Gates Foundation; BARDA Biomedical Advanced"/>
 <result pre="Commission; BMGF Bill &amp;amp; Melinda Gates Foundation; BARDA Biomedical Advanced" exact="Research and Development" post="Authority; DTRA Defense Threat Reduction Agency; WHO World Health"/>
 <result pre="Gates Foundation; BARDA Biomedical Advanced Research and Development Authority; DTRA" exact="Defense Threat Reduction Agency;" post="WHO World Health Organization; PDs product developers; CMOs contract"/>
 <result pre="Research and Development Authority; DTRA Defense Threat Reduction Agency; WHO" exact="World Health Organization;" post="PDs product developers; CMOs contract manufacturing organizations; GHIF Global"/>
 <result pre="Health Investment Fund; GAVI Global Alliance for Vaccines and Immunization;" exact="UNICEF" post="United Nations International Children’s Emergency Fund; PAHO Pan American"/>
 <result pre="Investment Fund; GAVI Global Alliance for Vaccines and Immunization; UNICEF" exact="United Nations" post="International Children’s Emergency Fund; PAHO Pan American Health Organization;"/>
 <result pre="Coalition for Epidemic Preparedness Innovations portfolio WHO R&amp;amp;D Blueprint The" exact="World Health Organization" post="(WHO) developed a list of diseases and pathogens to"/>
 <result pre="MERS-CoV Phase I Nipah Preclinical Profectus BioSciences, Emergent BioSolutions, and" exact="PATH" post="Lassa US$36.0 million Recombinant virus Preclinical Nipah US$25.0 million"/>
 <result pre="million Recombinant virus Preclinical Nipah US$25.0 million Protein subunit Preclinical" exact="International AIDS Vaccine Initiative" post="(IAVI) Lassa US$54.9 million Recombinant virus Preclinical IDT Biologika"/>
 <result pre="million Recombinant virus Phase I MERS-CoV Preclinical Chikungunya Phase III" exact="University of Tokyo" post="Nipah US$31.0 million Recombinant virus Phase I Inovio Pharmaceuticals"/>
 <result pre="Inovio Pharmaceuticals Lassa US$56.0 million DNA Preclinical MERS-CoV Phase II" exact="Colorado State University" post="Rift Valley fever US$9.5million Attenuated virus Preclinical Wageningen Bioveterinary"/>
 <result pre="I Public health vaccines Nipah US$43.6 million Recombinant virus Preclinical" exact="Imperial College London" post="Marburg US$8.4 million RNA Preclinical Influenza Rabies CureVac Lassa"/>
 <result pre="Lassa US$34.0 million RNA Preclinical Phase I Rabies Yellow fever" exact="University of Queensland" post="MERS-CoV US$10.6 million Recombinant protein Preclinical Influenza Respiratory syncytial"/>
 <result pre="Recent funding has been made available in partnership with the" exact="European Commission" post="for RVF and Chikungunya. Two RVF vaccine candidates are"/>
 <result pre="validated animal models acceptable to regulatory authorities. In 2002 the" exact="U.S. Food and Drug Administration" post="(FDA) finalized the Animal Efficacy Rule (also known as"/>
 <result pre="animal models acceptable to regulatory authorities. In 2002 the U.S." exact="Food and Drug Administration" post="(FDA) finalized the Animal Efficacy Rule (also known as"/>
 <result pre="the model by regulatory agencies. It is aligning with the" exact="National Centre for the Replacement, Refinement and Reduction of Animals in Research" post="(NC3Rs) guidelines to accelerate the development of models and"/>
 <result pre="Abbreviations AESIs Adverse events of special interest BARDA Biomedical Advanced" exact="Research and Development" post="Authority BMBF Federal Ministry for Education and Research BMGF"/>
 <result pre="Gates Foundation BNITM Bernhard Nocht Institute for Tropical Medicine CDC" exact="Centers for Disease Control and Prevention" post="CEPI Coalition for Epidemic Preparedness Innovations CMC Chemistry, Manufacturing"/>
 <result pre="Controls DRC Democratic Republic of the Congo DS/DP Downstream/upstream DTRA" exact="Defense Threat Reduction Agency" post="EC European Commission ECBS Expert Committee on Biological Standardization"/>
 <result pre="the Congo DS/DP Downstream/upstream DTRA Defense Threat Reduction Agency EC" exact="European Commission" post="ECBS Expert Committee on Biological Standardization EIDs Emerging infectious"/>
 <result pre="Collaboration for Infectious Disease Preparedness GMP Good manufacturing practice IAVI" exact="International AIDS Vaccine Initiative" post="IMI Innovative Medicines Initiative IRPs International reference preparations LMIC"/>
 <result pre="East respiratory syndrome coronavirus Meta-DSMB Metadata safety monitoring board MSF" exact="Médecins Sans Frontières" post="NC3Rs National Centre for the Replacement, Refinement and Reduction"/>
 <result pre="Meta-DSMB Metadata safety monitoring board MSF Médecins Sans Frontières NC3Rs" exact="National Centre for the Replacement, Refinement and Reduction of Animals in Research" post="NIBSC National Institute for Biological Standards and Control NIH"/>
 <result pre="Research NIBSC National Institute for Biological Standards and Control NIH" exact="National Institutes of Health" post="PAHO Pan American Health Organization PDs Product developers PoC"/>
 <result pre="hearing loss SOPs Standard operating procedures TPPs Target product profiles" exact="UNICEF" post="United Nations International Children’s Emergency Fund VHFC Viral Hemorrhagic"/>
 <result pre="loss SOPs Standard operating procedures TPPs Target product profiles UNICEF" exact="United Nations" post="International Children’s Emergency Fund VHFC Viral Hemorrhagic Fever Consortium"/>
 <result pre="Fund VHFC Viral Hemorrhagic Fever Consortium VLPs Virus-like particles WHO" exact="World Health Organization" post="The original version of this article was revised: In"/>
 <result pre="Sevilla JP Epidemics and economics 2018 5. Bell DM collab:" exact="World Health Organization" post="Working Group on Prevention of International and Community Transmission"/>
 <result pre="Vet Pathol 2010 47 774 778 10.1177/0300985810372506 20551476 29. collab:" exact="U.S. Department of Health and Human Services" post="FaDA collab: Center for Drug Evaluation and Research (Cder)"/>
 <result pre="Pathol 2010 47 774 778 10.1177/0300985810372506 20551476 29. collab: U.S." exact="Department of Health" post="and Human Services FaDA collab: Center for Drug Evaluation"/>
</results>
